Truveris

Technology and data analytics for pharmacy benefits

New York City, New York, United States

About Truveris

Truveris operates in the prescription drug industry, focusing on the pharmacy supply chain to simplify its complexities. The company provides technology and data analytics solutions to various clients, including payers, brokers, and pharmaceutical manufacturers. Their services include cost containment strategies, clinical guidance, and custom-branded pharmacy practice programs that help benefits advisors enhance their offerings. Truveris also develops patient access programs to assist pharmaceutical brands in effectively reaching patients and adapting to market changes. A key aspect of their work involves addressing regulatory challenges, ensuring clients can navigate issues like product recalls. The goal of Truveris is to deliver clear insights into pharmacy benefits, ultimately improving employee health, productivity, and satisfaction.

New York City, New YorkHeadquarters
2009Year Founded
$67.2MTotal Funding
SERIES_ECompany Stage
Data & Analytics, HealthcareIndustries
51-200Employees

Risks

Increased competition from new entrants could reduce market share.
Challenges in maintaining data privacy with expanding data-driven solutions.
Rapid technological advancements could render current solutions obsolete.

Differentiation

Truveris offers a transparent platform replacing traditional pharmacy benefit manager models.
The company provides custom-branded pharmacy practice programs for benefits advisors.
Truveris builds patient access programs predicting market shifts for sustainable design.

Upsides

Collaboration with Mark Cuban's company could lead to innovative cost-saving strategies.
$15M Series E funding enhances technology platform and market reach.
New C-suite appointments strengthen operational and commercial strategies.

Funding

Total raised$67.17 M
Latest valuation$125.00 M
StageSERIES_E
$15
$125.00 M
SERIES D
8/31/2017
$25
$125.00 M
EARLY VC
2/29/2016
$2
$12.50 M
SERIES B
1/31/2012
$10
$50.00 M
SERIES A
1/31/2011
$4
$19.00 M